Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial) : Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia
The multi-centre COVIDOC study will evaluate the efficacy and safety of the use of hydroxychloroquine (10 days) combined with azithromycin (5 days) compared to hydroxychloroquine (10 days) in the the clinical evolution by the ordinal scale of 7 points in adults hospitalized outside Intensive care unit with pneumonia caused by infection by the SARS-CoV2 virus in France..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
ClinicalTrials.gov - (2021) vom: 15. Dez. Zur Gesamtaufnahme - year:2021 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: April 15, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 |
---|
Study ID: |
NCT04345861 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003359174 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003359174 | ||
003 | DE-627 | ||
005 | 20230425203917.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2021 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003359174 | ||
035 | |a (UBBS_Klinische_Studien)NCT04345861 | ||
035 | |a (UBBS_Klinische_Studien)RECHMPL20_168 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial) |b Randomized Trial Assessing Efficacy and Safety of Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for Hospitalized Adults With COVID-19 Pneumonia |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: April 15, 2020, Last downloaded: ClinicalTrials.gov processed this data on December 27, 2021, Last updated: December 29, 2021 | ||
520 | |a The multi-centre COVIDOC study will evaluate the efficacy and safety of the use of hydroxychloroquine (10 days) combined with azithromycin (5 days) compared to hydroxychloroquine (10 days) in the the clinical evolution by the ordinal scale of 7 points in adults hospitalized outside Intensive care unit with pneumonia caused by infection by the SARS-CoV2 virus in France. | ||
650 | 2 | |a COVID-19 | |
650 | 2 | |a Pneumonia | |
650 | 2 | |a Coronavirus Infections | |
650 | 2 | |a Pneumonia, Viral | |
650 | 4 | |a Medical Condition: Coronavirus Infection, Pneumonia, Viral | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Terminated | |
650 | 4 | |a Phase: Phase 2, Phase 3 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2021) vom: 15. Dez. |
773 | 1 | 8 | |g year:2021 |g day:15 |g month:12 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04345861 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |j 2021 |b 15 |c 12 |